Development of a synthetic bioactivated membrane dressing
In plain English
AI plain-English summaryA synthetic wound dressing that actively prevents scarring is being developed to replace expensive, variable-quality human amniotic membrane currently used in clinics. Scarring after burns or traumatic injury can permanently impair movement, sight, or function. Existing synthetic dressings prevent infection and dehydration but do nothing to stop scar formation. Amniotic membrane, the gold standard for inhibiting corneal scarring, is costly and inconsistent in quality. This project builds on a prototype membrane loaded with Decorin—the natural anti-scarring agent found in amniotic tissue—that has already shown sustained release and scar inhibition in lab and animal tests. If successful, the team will scale up manufacturing to commercially viable quantities, gain a CE mark, and demonstrate safety and efficacy in human partial-thickness burns. The dressing is a platform technology: immediate use would be for burns—which affect roughly 175,000 hospital admissions per year in the UK—but it could also be adapted for chronic ulcers, surgical adhesions, and other wounds where scarring causes lasting harm. The impact is not about everyday convenience; it is about preventing permanent loss of function in patients who would otherwise face reduced mobility or blindness.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Health Innovation Challenge Fund AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know